Retrospective Study
Copyright ©The Author(s) 2019.
World J Gastroenterol. Oct 7, 2019; 25(37): 5655-5666
Published online Oct 7, 2019. doi: 10.3748/wjg.v25.i37.5655
Table 1 Demographic and clinical characteristics of patients with advanced gallbladder adenocarcinoma and the calculation and rank of importance for prognostic factors in survival time
VariableValueFrequency, n (%)Priori probability (%)Posterior probability (%)ImportanceRank
Sex1 (male)261 (31.91)33.2648.690.027416
2 (female)557 (68.09)66.7254.05
Age1 (19-64)256 (31.30)30.8439.550.108710
2 (65-75)258 (31.54)31.7142.31
3 (76-97)304 (37.16)37.4656.74
Grade1 (well)70 (8.56)8.3643.750.13838
2 (moderately)363 (44.38)45.3037.69
3 (poorly)376 (45.97)45.8256.27
4 (undifferentiated)9 (1.10)0.5266.67
Positive Ln0 (0)172 (21.03)65.2647.930.073713
1 (1-3)229 (28.00)30.4743.19
2 (> 3)27 (3.30)4.2756.86
NA390 (47.68)
Number Ln0 (0)389 (47.56)46.5256.930.14406
1 (1-3)266 (32.52)34.4940.19
2 (4-6)76 (9.29)8.0134.78
3 (> 6)87 (10.64)10.9831.75
Surg Prim Site40627 (76.65)77.0049.320.106811
60191 (23.35)23.0038.64
Scope Reg Ln Sur0387 (47.31)46.6957.090.18244
15 (0.61)0.5233.33
37 (0.86)1.0516.67
4264 (32.27)33.8040.72
5153 (18.70)17.9433.98
61 (0.12)
71 (0.12)
Surg Oth Reg0659 (80.56)79.9748.800.12059
117 (2.08)2.4442.86
2121 (14.79)14.8140.00
415 (1.83)2.0933.33
56 (0.73)0.7025.00
Seer historic stage1197 (24.08)23.8748.910.029215
2514 (62.84)62.7245.56
4107 (13.08)13.4149.35
Tumor size0 (0-10 mm)20 (2.44)3.4939.690.079712
1 (11-30 mm)228 (27.87)40.6442.98
2 (31-50 mm)181 (22.13)31.1944.46
3(> 50 mm)132 (16.14)24.6857.31
NA257 (31.42)
T stage300 (T3)768 (93.89)92.8645.400.20453
400 (T4)50 (6.11)7.1465.85
N stage0 (N0)534 (65.28)64.9847.990.032114
100 (N1)284 (34.72)35.0244.78
AJCC stage520 (stage 3A)515 (62.96)62.7247.500.14237
530 (stage 3B)253 (30.93)30.1441.04
720 (stage 4A)50 (6.11)7.1468.85
Radiation0 (no)592 (72.37)71.7856.070.32611
1 (yes)226 (27.63)28.2223.46
Radiation sequence0 (no)592 (72.37)71.7856.070.18055
2 (radiation before surgery)4 (0.49)0.3550.00
3 (radiation after surgery)222 (27.14)27.8723.12
Chemo- therapy0 (no)473 (57.82)57.1458.840.27952
1(yes)345 (42.18)42.8630.89
Vital status1 (Survival)197 (24.08)
4 (Dead)621 (75.92)
Survival months≤ 9383 (46.82)46.86
> 9435 (53.18)53.14
Table 2 Confusion matrix, reliability, and accuracy of Bayesian network model
Survival time (n)≤ 9 m (n = 114)> 9 m (n = 130)
Confusion matrix (n)≤ 9 m (128)8444
> 9 m (116)3086
Reliability (%)≤ 9 m (128)65.62%34.38%
> 9 m (116)25.86%74.14%
Accuracy (%)≤ 9 m (128)73.68%33.85%
> 9 m (116)26.32%66.15%
Table 3 Survival prediction table as established by T stage, N stage, radiation, and chemotherapy
T stageN stageRadiationChemotherapy> 9 m (%)
300041.35
300158.29
301075.42
301176.62
310034.59
310164.08
311069.71
311180.71
400028.50
400144.14
401063.44
401164.95
410014.85
410137.03
411043.14
411157.97